Enhancing Our Understanding of Cell Types, Differentiation, and Disease Through Enhancers: An Interview with César Daniel Meléndez-Ramírez, MS
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Melendez-Ramirez C, Cuevas-Diaz Duran R, Barrios-Garcia T, Giacoman-Lozano M, Lopez-Ornelas A, Herrera-Gamboa J
. Dynamic landscape of chromatin accessibility and transcriptomic changes during differentiation of human embryonic stem cells into dopaminergic neurons. Sci Rep. 2021; 11(1):16977.
PMC: 8379280.
DOI: 10.1038/s41598-021-96263-1.
View
2.
Doi D, Magotani H, Kikuchi T, Ikeda M, Hiramatsu S, Yoshida K
. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. Nat Commun. 2020; 11(1):3369.
PMC: 7338530.
DOI: 10.1038/s41467-020-17165-w.
View
3.
Allis C, Jenuwein T
. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016; 17(8):487-500.
DOI: 10.1038/nrg.2016.59.
View
4.
Takahashi J
. iPS cell-based therapy for Parkinson's disease: A Kyoto trial. Regen Ther. 2021; 13:18-22.
PMC: 7794047.
DOI: 10.1016/j.reth.2020.06.002.
View
5.
Chang K, Huang C, Ou-Yang C, Ho C, Lin H, Hsu C
. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation. Stem Cell Res Ther. 2021; 12(1):508.
PMC: 8456557.
DOI: 10.1186/s13287-021-02585-2.
View